New flu pill VNT-101 enters first human safety tests
NCT ID NCT07169318
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 24 times
Summary
This early-stage study tests the safety of an experimental oral drug called VNT-101 in healthy adults aged 18 to 59. The study will give single or multiple doses to see how the body handles the drug and if any side effects occur. It does not aim to treat or cure influenza, but to gather initial safety data for future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Altasciences Inc - Kansas City
RECRUITINGOverland Park, Kansas, 66212, United States
Conditions
Explore the condition pages connected to this study.